Company Overview of Regen BioPharma Inc.
Regen Biopharma, Inc., a biotechnology company, focuses on the development of regenerative medical applications in the United States. It intends to provide various products, including HemaXellerate I, a cellular therapy designed to heal damaged bone marrow; HemaXellerate II, a donor endothelial cell based therapeutic product; and dCellVax, a gene silenced dendritic cell immunotherapy for the treatment of breast cancer. The company was founded in 2012 and is based in La Mesa, California. Regen Biopharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.
4700 Spring Street
La Mesa, CA 91942
Founded in 2012
Key Executives for Regen BioPharma Inc.
Total Annual Compensation: $300.0K
Chief Scientific Officer
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2014.
Regen BioPharma Inc. Key Developments
Regen Biopharma Inc. Identifies Second Generation Gene Silencing Candidates for Blocking Cancer Stem Cell Gene Target
Jan 8 15
Regen BioPharma Inc. announced the discovery and demonstration of in vitro efficacy of a second generation of gene silencing drug candidates with specificity to the cancer stem cell gene NR2F6. The Company has rights to an invention covered by a non-provisional patent application disclosing compositions of matter, protocols and methods of use of treatment for cancer and other diseases of aberrant cellular proliferation. The patent covers the use of its proprietary novel candidates administered as short interfering nucleic acid (siNA) antisense, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA). Proof-of-concept studies originally identifying NR2F6 as a target for cancer stem cells were performed by Dr. Christine Ichim, senior research consultant with Regen Biopharma, along with scientists at the University of Toronto. These studies showed that silencing of the NR2F6 gene in leukemia cells led to the cells losing their leukemic characteristics. Cancer stem cells, also known as the cancer initiating cells, are the cells in a cancer that are tumorigenic, meaning they have the ability to cause formation of new tumors when implanted in animals. Blocking their ability to self-renew by silencing NR2F6 transforms cancer cells in to a non-tumorigenic state by guiding cells toward a process called differentiation and cellular maturation.
Regen BioPharma Inc. Presents Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at American Society of Hematology Annual Meeting
Dec 11 14
Regen BioPharma Inc. announced that it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. This new drug target was identified by the company's senior research consultant, Dr. Christine Ichim. A drug target is a gene involved in a disease which researchers aim to inhibit its function in order to treat the disease. The company recently acquired intellectual property generated at the University of Toronto for inhibiting NR2F6. The work entitled NR2F6 (EAR-2) is a novel leukemia oncogene whose cellular function is to regulate terminal differentiation of Erythrocytes at the Proerythroblast Stage was presented as abstract #1337 at the Moscone Center in San Francisco on Saturday, December 6, 2014 by Dr. Christine Ichim, Senior Research Consultant to the company.
Regen BioPharma, Inc. Issues Investigational New Drug Application Number 16200 from the FDA
Nov 4 14
Regen BioPharma Inc. announced issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer. The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months. Regen's dCellVax therapy is based on US Patent # 8,389,708, acquired from Professor Wei-Ping Min at the University of Western Ontario, Canada, as well as a collaboration between Dr. Min and the Company's Chief Science Officer Dr. Thomas Ichim. Preclinical studies have demonstrated efficacy in mouse models of breast cancer and melanoma.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|